Symbols

TXG

10x Genomics·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 3

Stock Price Surged Significantly

Ample Liquidity

High Gross Profit Margin

Gap Up

Price Hits New Low

Price Hits 52-week Low

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About TXG

10x Genomics, Inc.

A life sciences leader that develops instruments, consumables and software for analyzing biological systems complexity of biology

Industry

Life Science Tools and Services

Established Date

07/02/2012

Listing Date

09/12/2019

Exchange

NASDAQ Stock Exchange

Full-time Employees

1,178

Fiscal Year Ends

12-31

Website

www.10xgenomics.com

Security Type

Common stock

Office address

6230 Stoneridge Mall Road, Pleasanton, California 94588

Business

Introduction

10x Genomics, Inc., was incorporated in Delaware on July 2, 2012. The company is a life science technology company focused on developing innovative products and solutions to explore, understand and master biology. The company's integrated research solutions include instruments, consumables and software for analyzing biological systems with resolution and scale that match the complexity of biology.

Company Financials

EPS

TXG has released its 2025 Q4 earnings. EPS was reported at -0.13, versus the expected -0.22, beating expectations. The chart below visualizes how TXG has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

TXG has released its 2025 Q4 earnings report, with revenue of 166.03M, reflecting a YoY change of 0.61%, and net profit of -16.25M, showing a YoY change of 66.85%. The Sankey diagram below clearly presents TXG's revenue sources and cost distribution.